RxDoctor Payments Data

Dinh Dam, MD

Internal Medicine · San Jose, CANPI 1518936616

Payments from drug & device makers

$4,849in general payments, 2019–2025

Across 102 payments — averaging $47.54 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$2K
  • Boehringer Ingelheim$545
  • Novo Nordisk$501
  • GSK$391
  • Amgen$374
  • Boston Scientific$303
  • plus $580 from 8 others

What the payments were for

  • Food & beverage$4,75598%
  • Education$942%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,849 in reported general payments places this provider in the 85th percentile of 13,581 internal medicine providers in California.

See all internal medicine providers in California

Medicare billing

Part B allowed, 2024
$17,621
Medicare patients
83
Services billed
147

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
FarxigaDapagliflozin Propanediol174$162,163
JardianceEmpagliflozin156$155,465
JanuviaSitagliptin Phosphate94$93,352
RybelsusSemaglutide51$75,273
EliquisApixaban48$61,860
TrulicityDulaglutide38$38,751
VascepaIcosapent Ethyl47$31,658
CreonLipase/Protease/Amylase17$17,555
Trelegy ElliptaFluticasone/Umeclidin/Vilanter23$16,911
LinzessLinaclotide18$13,335
Icosapent Ethyl18$8,025
Atorvastatin Calcium691$7,000
TradjentaLinagliptin11$6,218
Losartan-HydrochlorothiazideLosartan/Hydrochlorothiazide350$6,211
DapagliflozinDapagliflozin Propanediol11$5,937

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaFarxiga$2,156$162,163174 claims
Boehringer IngelheimJardiance, Tradjenta$545$161,684167 claims
MerckJanuvia$125$93,35294 claims
Novo NordiskRybelsus$501$75,27351 claims
PfizerEliquis$21$61,86048 claims
GSKTrelegy Ellipta$391$16,91123 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 13,581 internal medicine providers in California.

Other internal medicine in San Jose

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →